Actelis Networks (NASDAQ: ASNS) continues to demonstrate commercial momentum with today’s announcement of a new order from a member of a large Pan European Telecom Group for its GigaLine backhaul…
Posts published in “Wall Street Wire”
TL;DR: FDA Breakthrough for Revolution Medicine’s Daraxonrasib and Verastem’s Progress Further Highlight the Excitement Surrounding the KRAS-targeting landscape; Silexion Positioned as an Under-the-Radar Player in the Field as it Advances…
After Blockbuster Phase 3 Results in Surgical Infection Prevention, PolyPid Unveils 60-Day GLP-1 Delivery Tech as Pharma Giants Pay Billions for Similar Solutions In the frenzy surrounding GLP-1 weight loss…
Company demonstrates rapid weight loss in animal models with potential best-in-class oral MC4R therapy Palatin Technologies (OTCQB: PTNT) (NYSE: PTN) has just released compelling preclinical efficacy data for PL7737, its…
Under the Radar Phage Therapy Trailblazer Begins Next Chapter in Fight Against Antibiotic-Resistant Infections BiomX (NYSE: PHGE) just announced that is successfully completed the first patient dosing in its Phase…
New study reveals Nuvectis Pharma’s NXP900 to be safe to use with CYP3A, the enzyme pathway through which many leading NSCLC therapies are metabolized; NXP900 could be come the ideal…
Wall Street Analysts Think PolyPid, a $35M BioPharma Player is Significantly Undervalued, Here’s Why
Wall Street Analysts Think PolyPid, a $35M BioPharma Player is Significantly Undervalued, Here’s Why
In the competitive landscape of biotechnology investments, discovering undervalued opportunities with significant upside potential requires careful analysis of clinical milestones, market positioning, and Wall Street sentiment. PolyPid Ltd. (NASDAQ: PYPD),…
Imagine a world where managing multiple chronic conditions isn’t a nightmare of fragmented care, endless appointments, and mounting medical bills. This isn’t a futuristic fantasy, it’s the vision of DarioHealth…
Surgical infection prevention breakthrough demonstrates 58% infection reduction as company secures funding through regulatory approval PolyPid Ltd. (NASDAQ: PYPD)* announced Tuesday that it has secured $26.7 million through warrant exercises…
Rumours have swirled for months about a new drone quietly used in Israel’s most volatile flash‑points—small enough to launch from a backpack, yet lethal enough to end a firefight with…